BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31481512)

  • 1. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
    Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
    Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
    Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
    Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laminin-associated integrins mediate Diffuse Intrinsic Pontine Glioma infiltration and therapy response within a neural assembloid model.
    Sinha S; Huang MS; Mikos G; Bedi Y; Soto L; Lensch S; Ayushman M; Bintu L; Bhutani N; Heilshorn SC; Yang F
    Acta Neuropathol Commun; 2024 May; 12(1):71. PubMed ID: 38706008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
    Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence.
    Sharma M; Barravecchia I; Teis R; Cruz J; Mumby R; Ziemke EK; Espinoza CE; Krishnamoorthy V; Magnuson B; Ljungman M; Koschmann C; Chandra J; Whitehead CE; Sebolt-Leopold JS; Galban S
    Mol Cancer Ther; 2024 Jan; 23(1):24-34. PubMed ID: 37723046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
    Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
    Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
    Dalle Ore C; Coleman C; Gupta N; Mueller S
    Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
    Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
    Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.
    Noll A; Myers C; Biery MC; Meechan M; Tahiri S; Rajendran A; Berens ME; Paine D; Byron S; Zhang J; Winter C; Pakiam F; Leary SES; Cole BL; Jackson ER; Dun MD; Foster JB; Evans MK; Pattwell SS; Olson JM; Vitanza NA
    Neoplasia; 2023 Sep; 43():100921. PubMed ID: 37603953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature.
    Dimentberg E; Marceau MP; Lachance A; Bergeron-Gravel S; Saikali S; Crevier L; Bourget C; Hawkins C; Jabado N; Giannakouros P; Renzi S; Larouche V
    J Pediatr Hematol Oncol; 2024 May; 46(4):211-215. PubMed ID: 38573000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
    Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multimodal imaging-based classification for pediatric diffuse intrinsic pontine gliomas.
    Pan C; Zhang M; Xiao X; Kong L; Wu Y; Zhao X; Sun T; Zhang P; Geng Y; Zuo P; Wang Y; Li X; Gu G; Li T; Wu Z; Zhang J; Zhang L
    Neurosurg Rev; 2023 Jun; 46(1):151. PubMed ID: 37358632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Peroxide Removal Limits the Radiosensitization of Diffuse Intrinsic Pontine Glioma (DIPG) Cells by Pharmacologic Ascorbate.
    Solst SR; Mapuskar KA; Graham CH; King SA; Rheem R; Current K; Allen BG; Caster JM; Spitz DR; Howard ME
    Radiat Res; 2023 Nov; 200(5):456-461. PubMed ID: 37758035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
    Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
    J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated re-irradiation for diffuse intrinsic pontine glioma.
    Mankuzhy NP; Tringale KR; Dunkel IJ; Farouk Sait S; Souweidane MM; Khakoo Y; Karajannis MA; Wolden S
    Pediatr Blood Cancer; 2024 May; 71(5):e30929. PubMed ID: 38430472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.